Exponent, Inc, together with its subsidiaries, operates as a science and engineering consulting company worldwide. Its services include analysis of product development, product recall, regulatory compliance, and the discovery of potential problems related to products, people, property, and impending litigation. The company operates in two segments, Engineering and Other Scientific, and Environmental and Health.
Read More…
Industry, Sector and Symbol
Industry Management consulting services
Sub-IndustryResearch & Consulting Services
SectorBusiness Services
Phone650-326-9400
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$379.52 million
Profitability
Miscellaneous
Employees1,122
Next Earnings Date10/17/2019 (Estimated)
OptionableOptionable
Exponent (NASDAQ:EXPO) Frequently Asked Questions
What is Exponent's stock symbol?
Exponent trades on the NASDAQ under the ticker symbol "EXPO."
How often does Exponent pay dividends? What is the dividend yield for Exponent?
Exponent announced a quarterly dividend on Thursday, July 18th. Shareholders of record on Friday, September 6th will be paid a dividend of $0.16 per share on Friday, September 20th. This represents a $0.64 annualized dividend and a yield of 0.90%. The ex-dividend date of this dividend is Thursday, September 5th. View Exponent's Dividend History.
When did Exponent's stock split? How did Exponent's stock split work?
Shares of Exponent split on Thursday, June 7th 2018. The 2-1 split was announced on Tuesday, May 15th 2018. The newly created shares were issued to shareholders after the closing bell on Wednesday, June 6th 2018. An investor that had 100 shares of Exponent stock prior to the split would have 200 shares after the split.
How were Exponent's earnings last quarter?
Exponent, Inc. (NASDAQ:EXPO) announced its quarterly earnings data on Thursday, July, 18th. The business services provider reported $0.39 earnings per share for the quarter, beating analysts' consensus estimates of $0.33 by $0.06. The business services provider earned $106.50 million during the quarter, compared to the consensus estimate of $95.77 million. Exponent had a return on equity of 23.44% and a net margin of 19.64%. The company's revenue was up 11.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.34 EPS. View Exponent's Earnings History.
When is Exponent's next earnings date?
What price target have analysts set for EXPO?
4 brokerages have issued 12 month target prices for Exponent's stock. Their forecasts range from $73.00 to $81.00. On average, they expect Exponent's share price to reach $77.00 in the next twelve months. This suggests a possible upside of 8.9% from the stock's current price. View Analyst Price Targets for Exponent.
What is the consensus analysts' recommendation for Exponent?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exponent in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Exponent.
What are Wall Street analysts saying about Exponent stock?
Here are some recent quotes from research analysts about Exponent stock:
- 1. According to Zacks Investment Research, "Exponent, Inc., is a multidisciplinary organization of scientists, physicians, engineers and business consultants performing in-depth scientific research and analysis in over 90 technical disciplines. The company is an engineering and scientific consulting firm providing solutions to complex problems. The firm has been best known for analyzing accidents and failures to determine their causes, but in recent years it has become more active in assisting clients with human health, environmental and engineering issues associated with new products to help prevent problems in the future. The Company serves clients in the automotive, aviation, chemical, construction, consumer products, energy, government, health, insurance, manufacturing, technology and other sectors. " (9/18/2019)
- 2. Cantor Fitzgerald analysts commented, ": We maintain our Overweight rating on Exponent and our PT of $56. We believe the nature of the company’s business gives Exponent an advantage in its ability to deliver results regardless of the economic backdrop. The company reported low-single-digit revenue growth for 4Q18, slightly below expectations. We expect revenues to grow in the mid-to-high single-digit range for all of 2019, with the opportunity for upside to conservative guidance, in our opinion, as we believe catalysts exist in a number of areas." (2/1/2019)
Has Exponent been receiving favorable news coverage?
Media headlines about EXPO stock have been trending negative this week, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Exponent earned a news impact score of -2.9 on InfoTrie's scale. They also assigned news stories about the business services provider a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Exponent.
Who are some of Exponent's key competitors?
Some companies that are related to Exponent include Booz Allen Hamilton (BAH), Genpact (G), FTI Consulting (FCN), ICF International (ICFI), RMR Group (RMR), Huron Consulting Group (HURN), NIC (EGOV), Navigant Consulting (NCI), Gopher Protocol (GOPH), Apollo Medical (AMEH), The Hackett Group (HCKT), Blackrock Capital Investment (BKCC), Avalon Globocare (AVCO), Information Services Group (III) and ATIF (ATIF).
What other stocks do shareholders of Exponent own?
Who are Exponent's key executives?
Exponent's management team includes the folowing people:
- Dr. Paul R. Johnston, Exec. Chairman (Age 65)
- Dr. Catherine Ford Corrigan, Pres, CEO & Director (Age 50)
- Mr. Richard L. Schlenker Jr., Exec. VP, CFO & Corp. Sec. (Age 53)
- Dr. Harri K. Kytomaa, Group VP & Principal Engineer (Age 60)
- Dr. Steven J. Murray, Group VP & Principal Engineer (Age 44)
Who are Exponent's major shareholders?
Exponent's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (14.54%), BlackRock Inc. (14.54%), Vanguard Group Inc. (10.42%), Conestoga Capital Advisors LLC (4.67%), Price T Rowe Associates Inc. MD (2.05%) and Janus Henderson Group PLC (1.98%). Company insiders that own Exponent stock include Carol Lindstrom, Catherine Corrigan, Debra Zumwalt, Harri Kytomaa, John Pye, Paul R Johnston, Richard L Schlenker Jr and Richard Reiss. View Institutional Ownership Trends for Exponent.
Which institutional investors are selling Exponent stock?
EXPO stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Renaissance Technologies LLC, Russell Investments Group Ltd., WINTON GROUP Ltd, Copeland Capital Management LLC, Ellis Investment Partners LLC, Riverbridge Partners LLC and Atlanta Capital Management Co. L L C. Company insiders that have sold Exponent company stock in the last year include Carol Lindstrom, Harri Kytomaa, John Pye and Richard L Schlenker Jr. View Insider Buying and Selling for Exponent.
Which institutional investors are buying Exponent stock?
EXPO stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Morgan Stanley, Conestoga Capital Advisors LLC, Nicholas Company Inc., Moody Aldrich Partners LLC, D. E. Shaw & Co. Inc., SG Americas Securities LLC and Public Employees Retirement Association of Colorado. View Insider Buying and Selling for Exponent.
How do I buy shares of Exponent?
Shares of EXPO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Exponent's stock price today?
One share of EXPO stock can currently be purchased for approximately $70.73.
How big of a company is Exponent?
Exponent has a market capitalization of $3.67 billion and generates $379.52 million in revenue each year. The business services provider earns $72.25 million in net income (profit) each year or $1.25 on an earnings per share basis. Exponent employs 1,122 workers across the globe.View Additional Information About Exponent.
What is Exponent's official website?
How can I contact Exponent?
Exponent's mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The business services provider can be reached via phone at 650-326-9400 or via email at [email protected]
MarketBeat Community Rating for Exponent (NASDAQ EXPO)
MarketBeat's community ratings are surveys of what our community members think about Exponent and other stocks. Vote "Outperform" if you believe EXPO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXPO will underperform the S&P 500 over the long term. You may vote once every thirty days.
